Breaking B and T cell tolerance using cationic lipid-DNA complexes (CLDC) as a vaccine adjuvant with hepatitis B virus (HBV) surface antigen in transgenic mice expressing HBV

Antiviral Research

Volumn 90, Issue 3, 2011, Pages 227-230

  Morrey, John D ^a   Motter, Neil E ^a   Chang, Stella ^b   Fairman, Jeffery ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b Juvaris BioTherapeutics Inc   (United States)

Author keywords

Hepatitis B virus; Therapeutic vaccine; Transgenic mice

Indexed keywords

ENERGIX B VACCINE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; IMMUNOGLOBULIN G ANTIBODY; JVRS 100; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; IMMUNOGENICITY; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SPLEEN CELL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; B-LYMPHOCYTES; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNE TOLERANCE; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES; VACCINES, DNA;

HEPATITIS B VIRUS; MUS; MUS MUSCULUS;

EID: 79955817802     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.04.006     Document Type: Article

References (19)

1. Bernstein D.I., Earwood J.D., Bravo F.J., Cohen G.H., Eisenberg R.J., Clark J.R., Fairman J., Cardin R.D. Effects of herpes simplex virus type 2 glycoprotein vaccines and CLDC adjuvant on genital herpes infection in the guinea pig. Vaccine 2011, 29:2071-2078.
2. Bertoletti A., Gehring A. Therapeutic vaccination and novel strategies to treat chronic HBV infection. Expert Rev. Gastroenterol. Hepatol. 2009, 3:561-569.
3. Cavanaugh V.J., Guidotti L.G., Chisari F.V. Interleukin-12 inhibits hepatitis B virus replication in transgenic mice. J. Virol. 1997, 71:3236-3243.
4. Dienstag J.L. Hepatitis B virus infection. N. Engl. J. Med. 2008, 359:1486-1500.
5. Dow S.W., Schwarze J., Heath T.D., Potter T.A., Gelfand E.W. Systemic and local interferon gamma gene delivery to the lungs for treatment of allergen-induced airway hyperresponsiveness in mice. Hum. Gene Ther. 1999, 10:1905-1914.
6. Gowen B.B., Fairman J., Smee D.F., Wong M.H., Jung K.H., Pace A.M., Heiner M.L., Bailey K.W., Dow S.W., Sidwell R.W. Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res. 2006, 69:165-172.
7. Guidotti L.G., Matzke B., Schaller H., Chisari F.V. High-level hepatitis B virus replication in transgenic mice. J. Virol. 1995, 69:6158-6169.
8. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829.
9. Hong D.K., Chang S., Botham C.M., Giffon T.D., Fairman J., Lewis D.B. Cationic lipid/DNA complex-adjuvanted influenza A virus vaccination induces robust cross-protective immunity. J. Virol. 2010, 84:12691-12702.
10. Isogawa M., Robek M.D., Furuichi Y., Chisari F.V. Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J. Virol. 2005, 79:7269-7272.
11. Iyer R.P., Roland A., Jin Y., Mounir S., Korba B., Julander J.G., Morrey J.D. Anti-hepatitis B virus activity of ORI-9020, a novel phosphorothioate dinucleotide, in a transgenic mouse model. Antimicrob. Agents Chemother. 2004, 48:2318-2320.
12. Julander J.G., Colonno R.J., Sidwell R.W., Morrey J.D. Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res. 2003, 59:155-161.
13. Julander J.G., Sidwell R.W., Morrey J.D. Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res. 2002, 55:27-40.
14. Kakimi K., Isogawa M., Chung J., Sette A., Chisari F.V. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections. J. Virol. 2002, 76:8609-8620.
15. Kimura K., Kakimi K., Wieland S., Guidotti L.G., Chisari F.V. Interleukin-18 inhibits hepatitis B virus replication in the livers of transgenic mice. J. Virol. 2002, 76:10702-10707.
16. Livingston B.D., Alexander J., Crimi C., Oseroff C., Celis E., Daly K., Guidotti L.G., Chisari F.V., Fikes J., Chesnut R.W., Sette A. Altered helper T lymphocyte function associated with chronic hepatitis B virus infection and its role in response to therapeutic vaccination in humans. J. Immunol. 1999, 162:3088-3095.
17. Lobaina Y., Trujillo H., García D., Gambe A., Chacon Y., Blanco A., Aguilar J.C. The effect of the parenteral route of administration on the immune response to simultaneous nasal and parenteral immunizations using a new HBV therapeutic vaccine candidate. Viral Immunol. 2010, 23:521-529.
18. Morrey J.D., Bailey K.W., Korba B.E., Sidwell R.W. Utilization of transgenic mice replicating high levels of hepatitis B virus for antiviral evaluation of lamivudine. Antiviral Res. 1999, 42:97-108.
19. Morrey J.D., Motter N.E., Taro B., Lay M., Fairman J. Efficacy of cationic lipid-DNA complexes (CLDC) on hepatitis B virus in transgenic mice. Antiviral Res. 2008, 79:71-79.